COMP <GO>
CRL vs INCY // EV/EBITDA & P/E VALUATION
Charles River Laboratories International Inc. (NYSE) VS. Incyte Corp. (NASDAQ) • 15-METRIC TALLY: CRL 2
— INCY 10
▲ EV/EBITDA & P/E VALUATION LEADER: INCY
LAST: $359.41 (-4.44%) • MKT CAP: $17.95B
valuation
95.0x
LAST: $120.39 (+3.07%) • MKT CAP: $23.68B
valuation
12.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. INCY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | INCY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 92.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | 42.40% | -42.00 | INCY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 12.5x | +82.50 | INCY | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 4.99% | -1.89 | INCY | /fcf-yield <GO> |
| Operating Margin | 0.60% | 29.50% | -28.90 | INCY | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 25.00% | -28.60 | INCY | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 21.20% | -22.10 | INCY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 10.04 | -6.39 | INCY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | INCY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.7 | 50.0 | +22.70 | CRL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.01 | +0.14 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 15.5x | +7.50 | INCY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.95B | $23.68B | -$5.72B | INCY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | INCY REV | CRL GROSS % | INCY GROSS % | CRL FCF | INCY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $5.14B | — | 92.8% | $557.0M | $1.18B |
| FY 2024 | $4.05B | $4.24B | — | 92.6% | $552.3M | $144.5M |
| FY 2023 | $4.13B | $3.70B | — | — | $498.1M | $330.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
INCY // BETA 1.01